Liu Xiaoqing, Wang Miaoran, Wen Rui, Zhu Haoyue, Xiao Ying, He Qian, Shi Yangdi, Hong Zhe, Xu Bing
Shenyang Tenth People's Hospital, Shenyang Medical College, Shenyang, China.
The First Hospital of China Medical University, Shenyang, China.
Front Pharmacol. 2025 Jan 27;16:1506771. doi: 10.3389/fphar.2025.1506771. eCollection 2025.
This cohort study aimed to evaluate the prognostic outcomes of patients with acute ischemic stroke (AIS) and diabetes mellitus following intravenous thrombolysis, utilizing machine learning techniques. The analysis was conducted using data from Shenyang First People's Hospital, involving 3,478 AIS patients with diabetes who received thrombolytic therapy from January 2018 to December 2023, ultimately focusing on 1,314 patients after screening. The primary outcome measured was the 90-day Modified Rankin Scale (MRS). An 80/20 train-test split was implemented for model development and validation, employing various machine learning classifiers, including artificial neural networks (ANN), random forest (RF), XGBoost (XGB), and LASSO regression. Results indicated that the average accuracy of the XGB model was 0.7355 (±0.0307), outperforming the other models. Key predictors for prognosis post-thrombolysis included the National Institutes of Health Stroke Scale (NIHSS) and blood platelet count. The findings underscore the effectiveness of machine learning algorithms, particularly XGB, in predicting functional outcomes in diabetic AIS patients, providing clinicians with a valuable tool for treatment planning and improving patient outcome predictions based on receiver operating characteristic (ROC) analysis and accuracy assessments.
这项队列研究旨在利用机器学习技术评估急性缺血性卒中(AIS)合并糖尿病患者静脉溶栓后的预后结果。分析使用了沈阳第一人民医院的数据,纳入了2018年1月至2023年12月期间接受溶栓治疗的3478例AIS合并糖尿病患者,经筛选后最终聚焦于1314例患者。测量的主要结局指标是90天改良Rankin量表(MRS)。采用80/20训练-测试分割进行模型开发和验证,使用了各种机器学习分类器,包括人工神经网络(ANN)、随机森林(RF)、XGBoost(XGB)和LASSO回归。结果表明,XGB模型的平均准确率为0.7355(±0.0307),优于其他模型。溶栓后预后的关键预测因素包括美国国立卫生研究院卒中量表(NIHSS)和血小板计数。这些发现强调了机器学习算法,尤其是XGB,在预测糖尿病AIS患者功能结局方面的有效性,为临床医生提供了一个有价值的工具,用于治疗规划,并基于受试者工作特征(ROC)分析和准确性评估改善患者结局预测。